^
    Back
    Association details:
    Biomarker:BCR-ABL1 F359I
    Cancer:Chronic Myeloid Leukemia
    Drug:Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Treatment recommendations based on BCR-ABL1 mutation profile...The table below lists the BCR-ABL1 mutations that should not be treated with bosutinib, dasatinib or nilotinib in the second-line setting...Nilotinib…T315I, Y253H, E255K/V, or F359V/C/I or G250E
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    In particular, V299L, T315A and F317L/V/I/C are resistant to dasatinib. Y253H, E255K/V and F359V/C/I are resistant to nilotinib, and V299L to bosutinib.
    DOI:
    10.1093/annonc/mdx219